Asieris(SH:688176) Xin Lang Cai Jing·2025-12-24 01:39Core Viewpoint - Yahui Pharmaceutical experienced a decline of 1.52% in stock price on December 23, with a trading volume of 88.92 million yuan, indicating a potential shift in investor sentiment and market dynamics [1]. Financing Summary - On December 23, Yahui Pharmaceutical had a financing buy amount of 7.90 million yuan and a financing repayment of 9.46 million yuan, resulting in a net financing buy of -1.55 million yuan [1]. - The total financing and securities balance for Yahui Pharmaceutical reached 210 million yuan, accounting for 4.36% of its market capitalization, which is above the 70th percentile level over the past year, indicating a high financing level [1]. - The company had no shares sold short or repaid on December 23, with a short selling balance of 32,800 yuan and a short selling volume of 29,100 shares, which is above the 90th percentile level over the past year, suggesting a high level of short interest [1]. Company Performance - As of September 30, Yahui Pharmaceutical had 25,200 shareholders, a decrease of 1.06% from the previous period, while the average circulating shares per person increased by 16.41% to 17,294 shares [2]. - For the period from January to September 2025, Yahui Pharmaceutical reported a revenue of 216 million yuan, representing a year-on-year growth of 55.74%, while the net profit attributable to the parent company was -24.9 million yuan, reflecting an 8.08% increase year-on-year [2]. - Among the top ten circulating shareholders, Penghua Medical Technology Stock A ranked as the seventh largest shareholder, holding 6.14 million shares, which is a decrease of 401,700 shares compared to the previous period [2].